Full Text View
Tabular View
No Study Results Posted
Related Studies
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder
This study has been completed.
Study NCT00064246   Information provided by National Cancer Institute (NCI)
First Received: July 8, 2003   Last Updated: February 6, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lymphoma
Lymphoproliferative Disorder
Additional conditions recognized in this trial
Disease
Lymphoproliferative Disorders
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Neoplasms
Neoplasms by Histologic Type
Pathologic Processes
Interventions listed in this trial
rituximab
yttrium Y 90 ibritumomab tiuxetan
Additional drug interventions recognized in this trial
Antibodies, Monoclonal
More general drug interventions related to this trial
Antineoplastic Agents
Antirheumatic Agents
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
AIDS Associated Malignancies Clinical Trials Consortium
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services